枯草杆菌二联活菌肠溶胶囊治疗肠易激综合征效果和安全性的Meta分析

Meta-analysis of the efficacy and safety of live combined bacillus subtilis enteric-coated capsules in the treatment of irritable bowel syndrome

目的采用Meta分析方法评价枯草杆菌二联活菌肠溶胶囊治疗肠易激综合征(IBS)的效果及安全性。方法系统检索了PubMed、Embase、中国生物医学文献、中国知网、万方、维普、Cochrane Library等数据库,检索时间截止至2023年6月。观察组采用枯草杆菌二联活菌肠溶胶囊单用或联合其他药物治疗,对照组采用其他药物单药或联合治疗。利用RevMan 5.4.1软件进行Meta分析。结果Meta分析结果显示,观察组总有效率优于对照组(相对危险度=1.20,P<0.001),腹痛、腹泻症状发生率均低于对照组(均P<0.05),而2组不良反应发生率差异无统计学意义(比值比=0.80,P=0.28)。亚组分析结果显示,观察组腹泻型IBS和便秘型IBS患者的治疗总有效率均高于对照组(均P<0.05)。结论基于目前的文献证据,枯草杆菌二联活菌肠溶胶囊治疗IBS有效性及安全性均较好。

Objective To evaluate the efficacy and safety of live combined bacillus subtilis enteric-coated capsules in the treatment of irritable bowel syndrome(IBS)by Meta-analysis.Methods PubMed,Embase,CBM,CNKI,Wanfang,VIP,Cochrane Library and other databases were systematically searched until June 2023.The observation group was treated with live combined bacillus subtilis enteric-coated capsules alone or combined with other drugs,and the control group was treated with other drugs alone or combined.RevMan 5.4.1 software was used for Meta-analysis.Results Meta-analysis showed that the total effective rate of the observation group was better than that of the control group(relative risk=1.20,P<0.001),and the incidences of abdominal pain and diarrhea symptoms were lower than those of the control group(all P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(odds ratio=0.80,P=0.28).Subgroup analysis showed that the total effective rates of the observation group were higher than those of the control group in diarrhea-predominant IBS and constipation-predominant IBS(both P<0.05).Conclusion Based on the current literature evidence,live combined bacillus subtilis enteric-coated capsules are effective and safe in the treatment of IBS.